BAY-3827

• CAT Number: I042676
• CAS Number: 2377576-35-5
• Molecular Formula: C27H25FN6O
• Molecular Weight: 468.53
• Purity: ≥95%
• Synonyms: N-[5-(3,5-dicyano-1,2,6-trimethyl-4H-pyridin-4-yl)-6-fluoro-7-methyl-1H-indazol-3-yl]-2-ethylbenzamide
• InChI: InChI=1S/C27H25FN6O/c1-6-17-9-7-8-10-18(17)27(35)31-26-20-11-19(24(28)14(2)25(20)32-33-26)23-21(12-29)15(3)34(5)16(4)22(23)13-30/h7-11,23H,6H2,1-5H3,(H2,31,32,33,35)
• InChIKey: OZFFKOSQNBBYCA-UHFFFAOYSA-N
• SMILES: CCC1=CC=CC=C1C(=O)NC2=NNC3=C(C(=C(C=C32)C4C(=C(N(C(=C4C#N)C)C)C)C#N)F)C

BAY-3827（Cat No.:I042676）is an experimental compound being investigated for its potential therapeutic applications, particularly in oncology. It works by targeting specific molecular pathways involved in tumor growth, survival, and metastasis. BAY-3827 is designed to inhibit key enzymes or receptors that regulate these processes, with the aim of reducing tumor proliferation and improving treatment outcomes. Early preclinical studies suggest promising anti-cancer activity, and the compound may also help overcome resistance to other therapies. Ongoing clinical trials are evaluating its safety, efficacy, and potential as a novel cancer treatment option, either alone or in combination with other therapies.